CP and COVID-19: Another study on CP therapy in severe COVID-19 patients(42) showed significant improvement of clinical symptoms, with an increase in oxyhemoglobin saturation after the third day of transfusion, reduction of pulmonary lesions, amelioration of routine laboratory criteria, and pulmonary function accompanied by rapid neutralization of viremia, using 200mL of CP derived from recently recovered donors with the neutralizing antibody titers between 1:160-640, approximately 16.5 days after onset of symptoms, associated to standard care and antiviral agents.